By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

BeiGene Co.,Ltd 

No.30 Science Park Road
Zhong-Guan-Cun Life Science Park
Changping District  Beijing    China
Phone: n/a Fax: n/a


SEARCH JOBS

BeiGene is a globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.

YEAR FOUNDED:

October 28, 2010

LEADERSHIP:

Founders: Xiaodong Wang, and John Oyler

CEO: John Oyler

CFO: Howard Liang

CMO (Medical): Eric Hedrick

JOBS:

Please click here for BeiGene job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email:
Ownership: Public

Web Site: BeiGene
Employees:
Symbol: BGNE
 



Industry
Pharmaceutical






Company News
BeiGene (BGNE) Presents Initial Phase I Data On BTK Inhibitor BGB-3111 Combined With Obinutuzumab At The 14th International Conference On Malignant Lymphoma And Announces Additional Planned Global Registrational Trials For BGB-3111 6/16/2017 8:59:55 AM
BeiGene (BGNE) Presents Updated Phase I Data On BTK Inhibitor BGB-3111 In Patients With Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma At The 14th International Conference On Malignant Lymphoma 6/14/2017 12:42:40 PM
BeiGene (BGNE) Presents Initial Phase I Data On Anti-PD-1 Antibody BGB-A317 Combined With PARP Inhibitor BGB-290 At The 2017 ASCO Annual Meeting 6/5/2017 1:01:59 PM
BeiGene (BGNE) Reports First Quarter 2017 Financial Results 5/11/2017 12:42:14 PM
BeiGene (BGNE) Announces Initiation Of First Pivotal Study In China Of PD-1 Antibody BGB-A317 4/21/2017 8:20:57 AM
BeiGene (BGNE) And Myriad Genetics (MYGN) Collaborate On Diagnostic For PARP Inhibitor 4/17/2017 10:41:05 AM
Myriad Genetics (MYGN) And BeiGene (BGNE) Sign Agreement To Develop Companion Diagnostics For Use With Beigene‚Äôs Novel PARP Inhibitor, BGB-290 4/6/2017 11:16:22 AM
BeiGene (BGNE) Presents Phase IB Data On RAF Dimer Inhibitor BGB-283 At The 2017 BeiGene (BGNE) Annual Meeting 4/3/2017 7:33:09 AM
Booming BeiGene (BGNE) To Build A $330 Million Biologics Manufacturing Facility In China 3/7/2017 6:27:23 AM
BeiGene (BGNE) Starts Global Phase III Trial Of BTK Inhibitor 1/30/2017 8:14:31 AM
1234567
//-->